• Profile
Close

Randomized controlled trial of the safety and immunogenicity of revaccination with tetanus-diphtheria-acellular pertussis vaccine (Tdap) in adults 10 years after a previous dose

Journal of the Pediatric Infectious Diseases Society Feb 14, 2018

Halperin SA, et al. - An observer-blinded, randomized controlled trial was performed to assess the safety and immunogenicity of revaccination with tetanus-diphtheria-acellular pertussis vaccine (Tdap) in adults 10 years (aged 18 to <65 years) after a previous dose. Findings revealed that in these adults, a second dose of Tdap vaccine was well tolerated and immunogenic. Findings thereby could facilitate consideration of providing Tdap booster doses to adults.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay